Xencor (NASDAQ:XNCR) Coverage Initiated at Mizuho

Equities research analysts at Mizuho began coverage on shares of Xencor (NASDAQ:XNCR) in a research note issued on Wednesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the stock. Raymond James initiated coverage on shares of Xencor in a research report on Thursday, March 14th. They set an “outperform” rating and a $27.85 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $40.00 target price on shares of Xencor in a research report on Sunday, May 12th. Nomura lowered shares of Xencor from a “neutral” rating to a “reduce” rating and dropped their target price for the stock from $28.00 to $21.00 in a research report on Friday, February 22nd. BidaskClub raised shares of Xencor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 7th. Finally, Piper Jaffray Companies boosted their target price on shares of Xencor to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $41.49.

XNCR traded up $0.32 during midday trading on Wednesday, hitting $31.70. 122,173 shares of the company’s stock traded hands, compared to its average volume of 212,274. The firm has a market cap of $1.76 billion, a PE ratio of -24.20 and a beta of 1.30. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.66 and a current ratio of 6.66. Xencor has a one year low of $27.75 and a one year high of $48.38.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.95. The business had revenue of $111.94 million for the quarter, compared to the consensus estimate of $60.05 million. On average, sell-side analysts anticipate that Xencor will post -0.08 earnings per share for the current fiscal year.

In other Xencor news, major shareholder John S. Stafford III purchased 1,100 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were purchased at an average price of $29.90 per share, for a total transaction of $32,890.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III purchased 5,500 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were acquired at an average price of $29.84 per share, for a total transaction of $164,120.00. The disclosure for this purchase can be found here. Insiders have acquired 74,152 shares of company stock worth $2,182,413 in the last quarter. Corporate insiders own 4.70% of the company’s stock.

Several large investors have recently modified their holdings of XNCR. Parametric Portfolio Associates LLC grew its position in shares of Xencor by 0.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 46,263 shares of the biopharmaceutical company’s stock valued at $1,437,000 after purchasing an additional 318 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Xencor by 1.2% in the 1st quarter. Wells Fargo & Company MN now owns 27,720 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 325 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Xencor by 2.6% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 19,139 shares of the biopharmaceutical company’s stock valued at $594,000 after buying an additional 480 shares during the last quarter. Equitec Specialists LLC boosted its holdings in shares of Xencor by 6.1% in the 1st quarter. Equitec Specialists LLC now owns 10,417 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 600 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Xencor by 8.8% in the 4th quarter. Legal & General Group Plc now owns 18,728 shares of the biopharmaceutical company’s stock valued at $678,000 after buying an additional 1,517 shares during the last quarter. Institutional investors own 83.51% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Article: How much can an individual set aside as a catch-up contribution?

The Fly

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply